Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The stable introduction of a functional beta-globin gene in haematopoietic stem cells could be a powerful approach to treat beta-thalassaemia and sickle-cell disease. Genetic approaches aiming to increase normal beta-globin expression in the progeny of autologous haematopoietic stem cells might circumvent the limitations and risks of allogeneic cell transplants. However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human beta-globin gene when it was linked to minimal regulatory sequences. Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine alpha-globin and two human betaA-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In beta-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After establishing that β-globin lentiviral vectors had successfully corrected models of β-thalassemia and sickle cell disease in mice, 17,18 we initiated a human clinical study of ex vivo gene therapy for the β-hemoglobinopathies”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [17]
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“, referred to as the locus control region (LCR), are linked to the globin gen”
BackgroundMalim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 1×
“Here we report how these problems may be overcome by using vectors derived from human immunodeficiency virus 1, a retrovirus that has the ability to regulate packaging of unspliced viral genome”
Hematology of Infancy and Childhood.
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-587_2 · Cited by 892
The Molecular Basis of Blood Diseases.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-6-950_3 · Cited by 632
Miyoshi, H., Smith, K. A., Mosier, D. E., Verma, I. M., & Torbett, B. E. (1999) · Science · doi:10.1126/science.283.5402.682 · Cited by 624
The "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601 · cited 1×
“The same outcome prevails in transgenic mice unless genomic elements encompassing DNase I hypersensitive sites (HS) located 60 kilobases (kb) upstream of the human β-globin gen”
BackgroundLooping versus linking: toward a model for long-distance gene activation
Bulger, M., & Groudine, M. (1999) · Genes & Development · doi:10.1101/gad.13.19.2465 · Cited by 484
Raj, S. R., Chen, S. R. W., Sheldon, R. S., Shah, A. N., Kantharia, B. K., Salzer, U., Grimbacher, B., Leung, A. K. C., Kamat, D., Kolovou, G. D., et al. (2009) · Encyclopedia of Molecular Mechanisms of Disease · doi:10.1007/978-3-540-29676-8_1731 · Cited by 475
Cited by
Items 301–400 of 622
The Use of Lentiviral Vectors to Obtain Transgenic Rats
Remy, S., Nguyen, T. H., Ménoret, S., Tesson, L., Usal, C., & Anegón, I. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-389-3_8 · Cited by 22
Allogeneic transplantation for haemoglobinopathies
Vassiliou, G. S., Amrolia, P. J., & Roberts, I. A. G. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2001.0174 · Cited by 22
Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia
Dong, A., & Rivella, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_6 · Cited by 21
Self-citationGenome-based therapeutic interventions for β-type hemoglobinopathies
Karamperis, K., Tsoumpeli, M. T., Kounelis, F., Koromina, M., Mitropoulou, C., Moutinho, C., & Patrinos, G. P. (2021) · Human Genomics · doi:10.1186/s40246-021-00329-0 · Cited by 21
The human desmin locus: Gene organization and LCR-mediated transcriptional control
Tam, J. L. Y., Triantaphyllopoulos, K. A., Todd, H., Raguz, S., de Wit, T., Morgan, J. E., Partridge, T. A., Makrinou, E., Grosveld, F. G., & Antoniou, M. N. (2006) · Genomics · doi:10.1016/j.ygeno.2006.01.009 · Cited by 21
“Clear signals of both the endogenous murine Des and the HBB transgene transcripts were observed in the highly vascularized spleen, kidney, liver, and lung tissues that were analyzed, the ratio of which was comparable to that seen in uterus and bladder (data not shown).”
BackgroundInfluentialTechniques for the Study of Adult Stem Cells: Be Fruitful and Multiply
Ramos, C. A., Bowman, T. V., Camargo, F. D., & Goodell, M. A. (2003) · BioTechniques · doi:10.2144/03343rv01 · Cited by 21
Desprat, R., & Bouhassira, E. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005956 · Cited by 21
Globin gene transfer for treatment of the β-thalassemias and sickle cell disease
Sadelain, M., Rivella, S., Lisowski, L., Samakoglu, S., & Rivière, I. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.002 · Cited by 21
Self-citationScreening and treatment of thalassemia
Su, Y., Xie, J., He, J., Shen, Y., Li, T., Huang, W., Tong, X., & Bian, Q. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120211 · Cited by 20
Engineering cell-based therapies to interface robustly with host physiology
Schwarz, K. A., & Leonard, J. N. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.019 · Cited by 20
Treating hemoglobinopathies using gene-correction approaches: promises and challenges
Cottle, R. N., Lee, C. M., & Bao, G. (2016) · Human Genetics · doi:10.1007/s00439-016-1696-0 · Cited by 20
Emerging therapies in β-thalassemia: toward a new era in management
Bou‐Fakhredin, R., Tabbikha, R., Daadaa, H., & Taher, A. T. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1752180 · Cited by 20
Morgan, R. A., Ma, F., Unti, M. J., Brown, D., Ayoub, P. G., Tam, C., Lathrop, L. E., Aleshe, B., Kurita, R., Nakamura, Y., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.006 · Cited by 20
THE PONTIFICAL ACADEMY OF SCIENCES
Sorondo, M. S. (2004) · International Seminar on Nuclear War and Planetary Emergencies · doi:10.1142/9789812702753_0001 · Cited by 20
Li, W., Xie, S., Guo, X., Gong, X., Wang, S., Lin, D., Zhang, J., Ren, Z., Huang, S., Zeng, F., et al. (2008) · Haematologica · doi:10.3324/haematol.12010 · Cited by 20
“first reported the alleviation of βthalassemic symptoms in a mouse model after engraftment of bone marrow cells stably transduced with a lentiviral vector (TNS9) carrying a large fragment of the human β-globin gene.(8) Long-term improvement of clinical symptoms of human β-thalassemia and sickle cell anemia was also re…”
BackgroundWard, M., Sattler, R. M., Grossman, I. R., Bell, A. J., Skerrett, D., Baxi, L., & Bank, A. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.07.002 · Cited by 20
Update on gene therapy for hereditary hematological disorders
Herzog, R. W., & Arruda, V. R. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.2.215 · Cited by 20
Hematti, P., Tuchman, S. A., Larochelle, A., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2004) · Stem Cells · doi:10.1634/stemcells.22-6-1062 · Cited by 20
Romero, Z. G., Campo-Fernández, B., Wherley, J., Kaufman, M. L., Urbinati, F., Cooper, A. R., Hoban, M. D., Baldwin, K. M., Lumaquin, D., Wang, X., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.12 · Cited by 19
García-Bates, T. M., Peslak, S. A., Baglole, C. J., Maggirwar, S. B., Bernstein, S. H., & Phipps, R. P. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0625-z · Cited by 19
Identification of Synthetic Endothelial Cell-Specific Promoters by Use of a High-Throughput Screen
Dai, C., McAninch, R. E., & Sutton, R. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6209-6221.2004 · Cited by 19
Development of gene therapy for blood disorders by gene transfer into haematopoietic stem cells
KARLSSON, S., OOKA, A., & WOODS, N. (2002) · Haemophilia · doi:10.1046/j.1365-2516.2002.00470.x · Cited by 19
Stiefelhagen, M., Sellner, L., Kleinschmidt, J. A., Jauch, A. S., Laufs, S., Wenz, F. K., Zeller, W. J., Früehauf, S., & Veldwijk, M. R. (2008) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-6-12 · Cited by 19
Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells
Doering, C. B., Archer, D. R., & Spencer, H. T. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.005 · Cited by 18
Novel therapies in β‐thalassaemia
Grech, L., Borg, K., & Borg, J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14918 · Cited by 19
Emergent treatments for β-thalassemia and orphan drug legislations
Costa, E., Cappellini, M. D., Rivella, S., Chilin, A., Alessi, E., Riccaboni, M., Leufkens, H. G. M., & Luzzatto, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103342 · Cited by 18
Self-citationGene Therapy for Hemoglobinopathies
Lidonnici, M. R., Scaramuzza, S., & Ferrari, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.138 · Cited by 18
Perinatal stem-cell and gene therapy for hemoglobinopathies
Surbek, D., Schoeberlein, A., & Wagner, A. M. (2008) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2008.03.002 · Cited by 18
Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization
Hu, P., Bi, Y., Ma, H., Suwanmanee, T., Zeithaml, B., Fry, N. J., Kohn, D. B., & Kafri, T. (2018) · Gene Therapy · doi:10.1038/s41434-018-0039-2 · Cited by 18
Yannaki, E., Psatha, N., Athanasiou, E., Karponi, G., Constantinou, V., Παπαδοπούλου, Α., Tasouli, A., Kaloyannidis, P., Batsis, I., Arsenakis, M., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.077 · Cited by 18
“…of several preclinical studies demonstrating correction of the thalassemic phenotype in animal models of hemoglobinopathies or in xenografts (May et al. , 2000; Pawliuk et al. , 2001; Imren et al. , 2002; Rivella et al. , 2003; Puthenveetil et al. , 2004; Miccio et al. , 2008) and paved the…”
Nicolini, F. E., Imren, S., Oh, I., Humphries, R. K., Leboulch, P., Fabry, M. E., Nagel, R. L., & Eaves, C. J. (2002) · Blood · doi:10.1182/blood-2002-02-0599 · Cited by 18
Bharadwaj, R. R., Trainor, C. D., Pasceri, P., & Ellis, J. (2003) · Blood · doi:10.1182/blood-2002-07-2086 · Cited by 18
Lentiviral Vectors for the Gene Therapy of Lympho-Hematological Disorders
Salmon, P., & Trono, D. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-56114-6_11 · Cited by 18
Gene Therapy for Hereditary Hematological Disorders
Herzog, R. W., & Hagstrom, J. N. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101020-00006 · Cited by 18
Yannaki, E., & Stamatoyannopoulos, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05576.x · Cited by 17
Morianos, I., Siapati, E. K., Pongas, G., & Vassilopoulos, G. (2011) · Gene Therapy · doi:10.1038/gt.2011.98 · Cited by 17
Persons, D. A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05581.x · Cited by 17
Development of Lentiviral Vectors with Regulated Respiratory Epithelial Expression In Vivo
Hendrickson, B., Senadheera, D., Mishra, S., Bui, K. C., Wang, X., Chan, B., Petersen, D., Pepper, K. A., & Lutzko, C. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0276oc · Cited by 17
Noya, F., Chien, W., Wu, X., Banerjee, N. S., Kappes, J. C., Broker, T. R., & Chow, L. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112441200 · Cited by 17
Primer on Medical Genomics Part X: Gene Therapy
Russell, S. J., & Peng, K.-W. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.11.1370 · Cited by 17
Analysis of alpha hemoglobin stabilizing protein overexpression in murine β‐thalassemia
Nasimuzzaman, M., Khandros, E., Wang, X., Kong, Y., Zhao, H., Weiss, D., Rivella, S., Weiss, M. J., & Persons, D. A. (2010) · American Journal of Hematology · doi:10.1002/ajh.21829 · Cited by 16
Self-citationTschulena, U., Peterson, K. R., Gonzalez, B., Fedosyuk, H., & Barbas, C. F. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1677 · Cited by 16
“A possible gene-based therapeutic intervention for these patients is the induction of fetal hemoglobin expression by an artificial transcription facto”
Patrinos, G. P., & Antonarakis, S. E. (2009) · Springer eBooks · doi:10.1007/978-3-540-37654-5_13 · Cited by 16
Taher, T. E. I., Tulone, C., Fatah, R., D’Acquisto, F., Gould, D., & Mageed, R. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.33 · Cited by 16
Effects on erythroid differentiation of platinum(II) complexes of synthetic bile acid derivatives
Lampronti, I., Bianchi, N., Zuccato, C., Medici, A., Bergamini, P., & Gambari, R. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.04.003 · Cited by 16
Lenti in red: progress in gene therapy for human hemoglobinopathies
Kalle, C. V., Baum, C., & Williams, D. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci23132 · Cited by 16
REVIEW The use of nonhuman primate models to improve gene transfer into haematopoietic stem cells
Dunbar, C. E. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00805.x · Cited by 16
Gene therapy for sickle cell disease
Olowoyeye, A., & Okwundu, C. I. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007652.pub2 · Cited by 16
Pluripotent Stem Cells in Research and Treatment of Hemoglobinopathies
Arora, N., & Daley, G. Q. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011841 · Cited by 15
“…studies to test the efficacy of lentiviruses containing various components of the human b-globin locus control region (LCR), promoter elements, and g-globin or b-globin gene constructs (May et al. 2000, 2002; Imren et al. 2002; Nishino et al. 2006; Han et al. 2007; Lisowski and Sadelain 2007).”
BackgroundCurative approaches for sickle cell disease: A review of allogeneic and autologous strategies
Bauer, D. E., Brendel, C., & Fitzhugh, C. D. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.014 · Cited by 15
β-Globin LCR and Intron Elements Cooperate and Direct Spatial Reorganization for Gene Therapy
Buzina, A., Lo, M., Moffett, A., Hotta, A., Fussner, E., Bharadwaj, R. R., Pasceri, P., García, J. V., Bazett‐Jones, D. P., & Ellis, J. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000051 · Cited by 15
Hematopoietic Cell Transplantation for Hemoglobinopathies
Krishnamurti, L., Bunn, H. F., Williams, A. M., & Tolar, J. (2007) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2007.10.002 · Cited by 15
Gene therapy for treatment of inherited haematological disorders
Herzog, R. W., Cao, O., Hagstrom, J. N., & Wang, L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.5.509 · Cited by 15
A Promising Genetic Approach to the Treatment of b-Thalassemia
May, C., & Sadelain, M. (2001) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00125-6 · Cited by 15
Self-citationCorrection of genetic blood defects by gene transfer
Cavazzana, M., & Hacein‐Bey‐Abina, S. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200111000-00008 · Cited by 15
Bradley, M. B., Sattler, R. M., Raftopoulos, H., Ward, M., Grossman, I. R., Townes, T. M., Ryan, T. M., & Bank, A. (2002) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.2002.v8.pm12234171 · Cited by 15
Gene therapy for sickle cell disease
Olowoyeye, A., & Okwundu, C. I. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007652.pub6 · Cited by 14
Coleman, M. A., Bridge, J. A., Lane, S., Dixon, C. M., Hill, G. R., Wells, J. W., Thomas, R., & Steptoe, R. J. (2012) · Blood · doi:10.1182/blood-2012-06-434100 · Cited by 14
Modelling human haemoglobin switching
Diepstraten, S. T., & Hart, A. H. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.06.001 · Cited by 14
Sadelain, M., Chang, A. H., & Lisowski, L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.238 · Cited by 14
Self-citationMaina, N., Li, Z., Li, X., Zhao, W., Han, Z., Bischof, D., Aslanidi, G., Zolotukhin, S., Weigel-Kelley, K. A., Rivers, A. E., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.173 · Cited by 14
Genetic Correction of Sickle Cell Anemia and β-Thalassemia: Progress and New Perspective
Perumbeti, A., & Malik, P. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.67 · Cited by 14
Hemoglobinopathies and Thalassemias
Peslak, S. A., & Sayani, F. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-812534-2.00009-6 · Cited by 14
Lavenu‐Bombled, C., Izac, B., Legrand, F., Cambot, M., Vigier, A., Massé, J., & Dubart‐Kupperschmitt, A. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0321 · Cited by 14
Sadelain, M. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.266 · Cited by 14
Self-citationImproving the Practice of Pain Management
Dahl, J. L. (2000) · JAMA · doi:10.1001/jama.284.21.2785-jms1206-3-1 · Cited by 14
The Current Status of Gene Therapy in Autologous Transplantation
Becker, P. S. (2005) · Acta Haematologica · doi:10.1159/000088409 · Cited by 14
“as CXCR4 is one of the major marrow-homing receptors of human hematopoietic stem cells, and it is believed to mediate the homing via the binding of stromal-derived factor-1. Improving Viral Entry into Bone-Marrow-Repopulating CellsTo circumvent the difficulty in obtaining a high proportion of cycling stem cells while…”
BackgroundTowards the genetic treatment of -thalassemia: new disease models, new vectors, new cells
Moi, P., & Sadelain, M. (2008) · Haematologica · doi:10.3324/haematol.12732 · Cited by 13
Self-citationLentiviral-mediated gene transfer – a patent review
Picanço‐Castro, V., Fontes, A. M., Russo, E. M. D. S., & Covas, D. T. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.5.525 · Cited by 13
Stem Cells: The Holy Grail of Regenerative Medicine
Singh, R. K., Gaikwad, S. M., Chatterjee, S., & Ray, P. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4372-7_2 · Cited by 13
Asparuhova, M. B., Kole, R., & Schümperli, D. (2004) · Gene Therapy and Regulation · doi:10.1163/1568558043967472 · Cited by 13
Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia
Eridani, S., & Mosca (2011) · Journal of Blood Medicine · doi:10.2147/jbm.s14942 · Cited by 13
Prospects for gene therapy using HIV-based vectors.
Yee, J., & ZAIA, J. A. (2001) · Somatic Cell and Molecular Genetics · doi:10.1023/a:1021034931852 · Cited by 13
ON THE ROAD TO GENE THERAPY FOR β-THALASSEMIA AND SICKLE CELL ANEMIA
Bank, A. (2008) · Pediatric Hematology and Oncology · doi:10.1080/08880010701773829 · Cited by 13
Falahati, R., Zhang, J., Flebbe-Rehwaldt, L., Shi, Y., Gerson, S. L., & Gaensler, K. M. L. (2012) · Molecular Therapy · doi:10.1038/mt.2012.136 · Cited by 12
Self-citationGene therapy for sickle cell disease
Olowoyeye, A., & Okwundu, C. I. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007652.pub7 · Cited by 12
Therapeutic effects of induced pluripotent stem cells in chimeric mice with -thalassemia
Yang, G., Shi, W., Hu, X., Zhang, J., Gong, Z., Guo, X., Ren, Z., & Zeng, F. (2014) · Haematologica · doi:10.3324/haematol.2013.087916 · Cited by 12
Worgall, S., & Crystal, R. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00034-3 · Cited by 12
Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors
Ellis, J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.ft-126 · Cited by 12
Genetic strategies for the treatment of sickle cell anaemia
Mansilla‐Soto, J., Rivière, I., & Sadelain, M. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08773.x · Cited by 12
“The TNS9 vector (May et al, 2000) encodes the human HBB gene deleted of a cryptic polyadenylation site within intron 2 (Sadelain et al, 1995), flanked by an extended promoter sequence, the HBB 3¢ proximal enhancer and large LCR segments spanning HS 2, 3 and 4.”
BackgroundInfluentialSelf-citationMutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C. F., Kustikova, O. S., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-181 · Cited by 12
Differences in F36VMpl-Based in Vivo Selection among Large Animal Models
Richard, R. E., de Claro, R. A., Yan, J., Chien, S. S., von Recum, H. A., Morris, J. C., Kiem, H., Dalgarno, D. C., Heimfeld, S., Clackson, T., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.005 · Cited by 12
Yasui, K., Furuta, R. A., Matsumoto, K., Tani, Y., & Fujisawa, J. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2004.11.003 · Cited by 12
Taking the good out of the bad: lentiviral-based gene therapy of the hemoglobinopathies
Stathopulos, P. B. (2003) · Biotechnology Advances · doi:10.1016/s0734-9750(03)00102-2 · Cited by 12
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Emerging cellular and gene therapies for congenital anemias
Ludwig, L. S., Khajuria, R. K., & Sankaran, V. G. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31529 · Cited by 11
“A number of b-globin gene-containing lentiviral vectors were subsequently shown to correct SCD and bthalassemia in mouse models [May et al., 2000; Pawliuk et al., 2001; Levasseur et al., 2003] and in human HSPCs transplanted into immunodeficient mice [Puthenveetil et al., 2004; Breda et al., 2012].”
BackgroundEngineering Globin Gene Expression
Davis, R., Gurumurthy, A., Hossain, M. A., Gunn, E. M., & Bungert, J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.004 · Cited by 11
“The first proof-of-concept study demonstrated high-level expression of a globin gene driven by large fragments of LCRHS2, HS3, and HS4, plus the b-globin promoter and 30 enhancer (TNS9; Figure 2) in a b-thalassemic mouse model.(42,43) A similar construct (HPV569) expressing the anti-sickling Q87 globin and also includ…”
MethodHematopoietic stem cell-based gene therapy against HIV infection: promises and caveats.
van Griensven, J., Clercq, E. D., & Debyser, Z. (2005) · PubMed · Cited by 11
Recent Progress on Genetic Diagnosis and Therapy for β-Thalassemia in China and Around the World
Zhang, J., Yan, J., & Zeng, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.228 · Cited by 11
“34 Inspired by May et al ., who first re-ported the lentiviral vector delivery of a b -globin gene to treat b -thalassemia in model mice, 35 Li et al . achieved direct-delivery of b -globin expressing genes using a lentiviral vector and observed phenotypic recovery in a mouse model.”
Effects of human γ‐globin in murine β‐thalassaemia
Nishino, T., Cao, H., Stamatoyannopoulos, G., & Emery, D. W. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06102.x · Cited by 11
“Likewise, most of these studies have also focused on the use of recombinant virus vectors for wild type (WT) or variant forms of human b-globin (May et al, 2000, 2002; Pawliuk et al, 2001; Imren et al, 2002), while relatively few have focused on the use of vectors for human c-globin (Person et al,…”
BackgroundNonhuman primate transgenesis: progress and prospects
Wolfgang, M. J., & Golos, T. G. (2002) · Trends in biotechnology · doi:10.1016/s0167-7799(02)02052-8 · Cited by 11
Gene therapy for the hemoglobin disorders.
Persons, D. A., & Nienhuis, A. W. (2003) · PubMed · Cited by 11
Development of Gene Therapy for Hemoglobin Disorders
Nienhuis, A. W., Hanawa, H., Sawai, N., Sorrentino, B. P., & Persons, D. A. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03238.x · Cited by 11
The Challenge of Painful Crisis in Sickle Cell Disease
Nagel, R. L. (2001) · JAMA · doi:10.1001/jama.286.17.2152 · Cited by 11
Advancing the care of β-thalassaemia patients with novel therapies.
Bou‐Fakhredin, R., Motta, I., & Cappellini, M. D. (2022) · Blood transfusion · doi:10.2450/2021.0265-21 · Cited by 10
Globin vector regulatory elements are active in early hematopoietic progenitor cells
Cabriolu, A., Odak, A., Zamparo, L., Yuan, H., Leslie, C. S., & Sadelain, M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.028 · Cited by 10
Self-citationSite-specific transfer of an intact β-globin gene cluster through a new targeting vector
Zhou, H., Zhao, N., Li, L., Dong, W.-J., Wu, X., Hao, D., Guo, Z.-C., Xia, K., Xia, J., Liu, D., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.074 · Cited by 10
Innovative Therapies for Hemoglobin Disorders
Sii-Felice, K., Nègre, O., Brendel, C., Tubsuwan, A., Morel-à-l’Huissier, E., Filardo, C., & Payen, E. (2020) · BioDrugs · doi:10.1007/s40259-020-00439-6 · Cited by 10
Felfly, H., & Trudel, M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300204 · Cited by 10
Gene therapy for chronic myelogenous leukemia
Verfaillie, C. M., McIvor, R. S., & Zhao, R. C. H. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01507-5 · Cited by 10
Metadata
- Authors
- May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Sadelain, Michel
- Venue
- Nature
- Published
- 2000-07
- Volume
- 406
- Issue
- 6791
- Pages
- 82-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1997170085
- Cited by
- 567
- References
- 34
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 10 · 2020: 10 · 2019: 16 · 2018: 26 · 2017: 18 · 2016: 16 · 2015: 15 · 2014: 13 · 2013: 22 · 2012: 24
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- James S. McDonnell Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- beta-thalassemia, sickle cell disease, lentiviral transduction, human beta-globin gene, hematopoietic stem cells, locus control region, hemoglobin synthesis, anemia, erythrocyte morphology, position effect, transcriptional silencing
- MeSH terms
- Animals, Cell Line, Female, Genetic Vectors, Globins, Hemoglobins, Humans, Male, Recombinant Proteins, Transduction, Genetic, Genetic Therapy, HIV-1, Bone Marrow Transplantation, Lentivirus, beta-Thalassemia, Gene Transfer Techniques, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.